Nicorette Invisi 15mg Patch

  • Name:

    Nicorette Invisi 15mg Patch

  • Company:
    info
  • Active Ingredients:

    Nicotine

  • Legal Category:

    Supply through general sale

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/07/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 7/6/2019

Click on this link to Download PDF directly

Johnson & Johnson (Ireland) Ltd

Johnson & Johnson (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name ACTIFED 30 mg/1.25 mg per 5 ml Syrup Active Ingredients Pseudoephedrine Hydrochloride, triprolidine hydrochloride
Medicine Name ACTIFED 60 mg / 2.5 mg Tablets Active Ingredients Pseudoephedrine Hydrochloride, triprolidine hydrochloride
Medicine Name Arret 2mg Hard Capsules Active Ingredients Loperamide Hydrochloride
Medicine Name Benylin Children's Chesty Coughs Active Ingredients Guaifenesin
Medicine Name Benylin Children's Dry Coughs Active Ingredients Diphenhydramine Hydrochloride, Levomenthol
Medicine Name Benylin Cough Medicine Syrup Active Ingredients Diphenhydramine Hydrochloride, Levomenthol
Medicine Name Benylin Day and Night Tablets Active Ingredients Diphenhydramine Hydrochloride, Paracetamol, Pseudoephedrine Hydrochloride
Medicine Name Benylin Dry Coughs Syrup Active Ingredients Dextromethorphan Hydrobromide, Diphenhydramine Hydrochloride, Levomenthol
Medicine Name Benylin Dual Action Dry Syrup Active Ingredients Dextromethorphan Hydrobromide, Pseudoephedrine Hydrochloride, triprolidine hydrochloride
Medicine Name Benylin Four Flu Tablets Active Ingredients Diphenhydramine Hydrochloride, Paracetamol, Pseudoephedrine Hydrochloride
Medicine Name Benylin Non- Drowsy for Chesty Coughs Active Ingredients Guaifenesin, Levomenthol
Medicine Name BENYLIN Non-Drowsy Dry Coughs, Syrup Active Ingredients Dextromethorphan Hydrobromide
Medicine Name Benylin Phlegm Cough plus Decongestant Syrup Active Ingredients Guaifenesin, Pseudoephedrine Hydrochloride
Medicine Name Benylin Phlegm Cough Syrup Active Ingredients Guaifenesin, Levomenthol
Medicine Name Calpol 120mg/5ml Infant Oral Suspension Active Ingredients Paracetamol
Medicine Name Calpol Infant 120mg/5ml Sugar Free Oral Suspension (bottle) Active Ingredients Paracetamol
Medicine Name Calpol Infant 120mg/5ml Sugar Free Oral Suspension (sachets) Active Ingredients Paracetamol
Medicine Name CALPOL Six Plus 250mg/5ml Oral Suspension Active Ingredients Paracetamol
Medicine Name CALPOL SIX PLUS 250mg/5ml SUGAR/COLOUR FREE ORAL SUSPENSION Active Ingredients Paracetamol
Medicine Name CALPOL Six Plus Fastmelts 250 mg Paracetamol OrodispersibleTablets Active Ingredients Paracetamol
Medicine Name Colpermin Gastro-Resistant Capsules Active Ingredients Peppermint Oil
Medicine Name Daktarin 2% w/w Cream Active Ingredients Miconazole nitrate
Medicine Name Daktarin 2% w/w Cutaneous Powder Active Ingredients Miconazole nitrate
Medicine Name DAKTARIN 20mg/g Oral Gel Active Ingredients Miconazole
Medicine Name Imodium 2 mg Capsules Active Ingredients Loperamide Hydrochloride
1 - 0 of 67 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 7 June 2019 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Supply through general sale

Updated on 5 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

PA Transfer from McNeil Healthcare (Ireland) Ltd to Johnson & Johnson (Ireland) Ltd. Change in PA number. Note the address and contact details remain the same.

Updated on 5 July 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 8 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 23 August 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through general sale

Updated on 23 August 2016 SmPC

Reasons for updating

  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Text highlighted in blue has been added:

4.9 Overdose

Excessive use of nicotine from either NRT and/or smoking might cause symptoms of an overdose. Symptoms of overdose are those of acute nicotine poisoning and include nausea, salivation, abdominal pain, diarrhoea, sweating, headache, dizziness, disturbed hearing and marked weakness. At high doses, these symptoms may be followed by hypotension, weak and irregular pulse, breathing difficulties, prostration, circulatory collapse and general convulsions. Doses of nicotine that are tolerated by adult smokers during treatment may produce severe symptoms of poisoning in small children and may prove fatal.

 

Suspected nicotine poisoning in a child should be considered a medical emergency and treated immediately.

 

Management of overdose

The administration of nicotine must be stopped immediately and the patient should be treated symptomatically.

 

Remove patch and rinse application site with water. Oral activated charcoal reduces gastrointestinal absorption of nicotine. Tachycardia causing circulatory impairment may require treatment with a b blocker. Excitation and convulsions may be treated with diazepam. Mechanically assisted ventilation should be instituted if necessary.

 

10.       Date of (Partial) Revision of the Text

10th August 2016

Updated on 23 August 2016 PIL

Reasons for updating

  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Text highlighted in blue has been added:

4.9 Overdose

Excessive use of nicotine from either NRT and/or smoking might cause symptoms of an overdose. Symptoms of overdose are those of acute nicotine poisoning and include nausea, salivation, abdominal pain, diarrhoea, sweating, headache, dizziness, disturbed hearing and marked weakness. At high doses, these symptoms may be followed by hypotension, weak and irregular pulse, breathing difficulties, prostration, circulatory collapse and general convulsions. Doses of nicotine that are tolerated by adult smokers during treatment may produce severe symptoms of poisoning in small children and may prove fatal.

 

Suspected nicotine poisoning in a child should be considered a medical emergency and treated immediately.

 

Management of overdose

The administration of nicotine must be stopped immediately and the patient should be treated symptomatically.

 

Remove patch and rinse application site with water. Oral activated charcoal reduces gastrointestinal absorption of nicotine. Tachycardia causing circulatory impairment may require treatment with a b blocker. Excitation and convulsions may be treated with diazepam. Mechanically assisted ventilation should be instituted if necessary.

 

10.       Date of (Partial) Revision of the Text

10th August 2016

Updated on 5 April 2016 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.1 added text "or Nicorette 15mg Inhaler"

Section 4.2 added text "heavy"
"(more than 20 cigarettes a day) or smokers"
Replaced "and" with "may be combined with"
Replaced "may be combined" with "or Nicorette 15mg Inhaler"
Added "or Nicorette 15mg Inhaler"
Replaced "felt" with "feels"
Added "of gum or 6 inhaler cartridges"
"or Nicorette 15mg Inhaler"
Replaced "felt" with "feels"
Added "of gum or 6 inhaler cartridges"
"or Nicorette 15mg Inhaler"
Added "or Nicorette Inhaler" three times

Section 10 replaced date with "March 2016"

Updated on 5 April 2016 PIL

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 4.1 added text "or Nicorette 15mg Inhaler"

Section 4.2 added text "heavy"
"(more than 20 cigarettes a day) or smokers"
Replaced "and" with "may be combined with"
Replaced "may be combined" with "or Nicorette 15mg Inhaler"
Added "or Nicorette 15mg Inhaler"
Replaced "felt" with "feels"
Added "of gum or 6 inhaler cartridges"
"or Nicorette 15mg Inhaler"
Replaced "felt" with "feels"
Added "of gum or 6 inhaler cartridges"
"or Nicorette 15mg Inhaler"
Added "or Nicorette Inhaler" three times

Section 10 replaced date with "March 2016"

Updated on 10 August 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.3 – QRD updates

 

Section 4.4 – additional warnings added:

The benefits of quitting smoking outweigh any risks associated with correctly administered nicotine replacement therapy (NRT).

 

A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:

 

·         Dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal’s angina, severe cardiac arrhythmias, recent cerebrovascular accident, and/or who suffer with uncontrolled hypertension should be encouraged to stop smoking with non-pharmacological interventions (such as counselling). If this fails, Nicorette Invisi Patch may be considered but as data on safety in this patient group are limited, initiation should only be under close medical supervision.

·         Diabetes Mellitus. Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when smoking is stopped and NRT is initiated, as reductions in nicotine-induced catecholamine release can affect carbohydrate metabolism.

·         Renal and hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.

·         Phaeochromocytoma and uncontrolled hyperthyroidism: Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.

·         Gastrointestinal Disease: Nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and NRT preparations should be used with caution in these conditions.

 

Patients with chronic dermatological disorders such as psoriasis, chronic dermatitis or urticaria should not apply Nicorette Invisi Patch to the affected areas. Erythema may occur.  If it is severe or persistent, treatment should be discontinued.

Danger in children: Doses of nicotine tolerated by smokers can produce severe toxicity in children that may be fatal. Products containing nicotine should not be left where they may be handled or ingested by children, see section 4.9 Overdose.

 

Transferred dependence: Transferred dependence can occur but is unusual and both less harmful and easier to break than smoking dependence.

 

Nicorette Invisi Patch should be removed prior to undergoing any Magnetic Resonance Imaging (MRI) procedures to prevent the risk of burns.

 

 

Section 4.5 – information on possible interaction with adenosine added:

Nicotine may possibly enhance the haemodynamic effects of adenosine i.e. increase in blood pressure and heart rate and also increased pain response (angina-pectoris type chest pain) provoked by adenosine administration.

 

 

 

 

Section 4.6 – information updated:

Women of childbearing potential/ contraception in males and females

In contrast to the well-known adverse effects of tobacco smoking on human conception and pregnancy, the effects of therapeutic nicotine treatment are unknown. Thus, whilst to date no specific advice regarding the need for female contraception has been found to be necessary, the most prudent state for women intending to become pregnant is to be both non-smoking, and not using NRT.

Whilst smoking may have adverse effects on male fertility, no evidence exists that particular contraceptive measures are required during NRT treatment by males.

 

Pregnancy:

Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or stillbirth. Stopping smoking is the single most effective intervention for improving the health of both pregnant smoker and her baby. The earlier abstinence is achieved the better.

Nicotine passes freely to the foetus and affects its breathing movements and circulation.  The effect on the circulation is dose-dependent.

Therefore, the pregnant smoker should always be advised to stop smoking completely without the use of nicotine replacement therapy.  The risk of continued smoking may pose a greater hazard to the foetus as compared with the use of nicotine replacement therapy products in a supervised cessation programme. Use of Nicorette Invisi Patch should only be initiated after advice from a physician. 

Lactation:

Nicotine passes freely into breast milk in quantities that may affect the child even in therapeutic dose.   Nicorette Patch should therefore be avoided  during breast-feeding.

Should smoking cessation not be achieved, use of the Nicorette Invisi Patch by breast feeding smokers should only be initiated after advice from a health care professional.
 

Fertility

In females tobacco smoking delays time to conception, decreases in-vitro fertilization success rates, and significantly increases the risk of infertility.   

In males tobacco smoking reduces sperm production, increases oxidative stress, and DNA damage.  Spermatozoa from smokers have reduced fertilizing capacity. 

The specific contribution of nicotine to these effects in humans is unknown.

 

 

Section 4.7 – QRD updates

 

Section 4.8 – additional AEs added, please refer to the SPC for details

 

 

SNAS 1293

 

 

 

 

 

 

Updated on 10 August 2015 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Free text change information supplied by the pharmaceutical company

Section 4.3 – QRD updates

 

Section 4.4 – additional warnings added:

The benefits of quitting smoking outweigh any risks associated with correctly administered nicotine replacement therapy (NRT).

 

A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:

 

·         Dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal’s angina, severe cardiac arrhythmias, recent cerebrovascular accident, and/or who suffer with uncontrolled hypertension should be encouraged to stop smoking with non-pharmacological interventions (such as counselling). If this fails, Nicorette Invisi Patch may be considered but as data on safety in this patient group are limited, initiation should only be under close medical supervision.

·         Diabetes Mellitus. Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when smoking is stopped and NRT is initiated, as reductions in nicotine-induced catecholamine release can affect carbohydrate metabolism.

·         Renal and hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.

·         Phaeochromocytoma and uncontrolled hyperthyroidism: Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.

·         Gastrointestinal Disease: Nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and NRT preparations should be used with caution in these conditions.

 

Patients with chronic dermatological disorders such as psoriasis, chronic dermatitis or urticaria should not apply Nicorette Invisi Patch to the affected areas. Erythema may occur.  If it is severe or persistent, treatment should be discontinued.

Danger in children: Doses of nicotine tolerated by smokers can produce severe toxicity in children that may be fatal. Products containing nicotine should not be left where they may be handled or ingested by children, see section 4.9 Overdose.

 

Transferred dependence: Transferred dependence can occur but is unusual and both less harmful and easier to break than smoking dependence.

 

Nicorette Invisi Patch should be removed prior to undergoing any Magnetic Resonance Imaging (MRI) procedures to prevent the risk of burns.

 

 

Section 4.5 – information on possible interaction with adenosine added:

Nicotine may possibly enhance the haemodynamic effects of adenosine i.e. increase in blood pressure and heart rate and also increased pain response (angina-pectoris type chest pain) provoked by adenosine administration.

 

 

 

 

Section 4.6 – information updated:

Women of childbearing potential/ contraception in males and females

In contrast to the well-known adverse effects of tobacco smoking on human conception and pregnancy, the effects of therapeutic nicotine treatment are unknown. Thus, whilst to date no specific advice regarding the need for female contraception has been found to be necessary, the most prudent state for women intending to become pregnant is to be both non-smoking, and not using NRT.

Whilst smoking may have adverse effects on male fertility, no evidence exists that particular contraceptive measures are required during NRT treatment by males.

 

Pregnancy:

Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or stillbirth. Stopping smoking is the single most effective intervention for improving the health of both pregnant smoker and her baby. The earlier abstinence is achieved the better.

Nicotine passes freely to the foetus and affects its breathing movements and circulation.  The effect on the circulation is dose-dependent.

Therefore, the pregnant smoker should always be advised to stop smoking completely without the use of nicotine replacement therapy.  The risk of continued smoking may pose a greater hazard to the foetus as compared with the use of nicotine replacement therapy products in a supervised cessation programme. Use of Nicorette Invisi Patch should only be initiated after advice from a physician. 

Lactation:

Nicotine passes freely into breast milk in quantities that may affect the child even in therapeutic dose.   Nicorette Patch should therefore be avoided  during breast-feeding.

Should smoking cessation not be achieved, use of the Nicorette Invisi Patch by breast feeding smokers should only be initiated after advice from a health care professional.
 

Fertility

In females tobacco smoking delays time to conception, decreases in-vitro fertilization success rates, and significantly increases the risk of infertility.   

In males tobacco smoking reduces sperm production, increases oxidative stress, and DNA damage.  Spermatozoa from smokers have reduced fertilizing capacity. 

The specific contribution of nicotine to these effects in humans is unknown.

 

 

Section 4.7 – QRD updates

 

Section 4.8 – additional AEs added, please refer to the SPC for details

 

 

SNAS 1293

 

 

 

 

 

 

Updated on 26 September 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 9 - Date of renewal of authorisation

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Renewal updates to product description and renewal date.

Updated on 26 September 2013 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 9 - Date of renewal of authorisation

Free text change information supplied by the pharmaceutical company

Renewal updates to product description and renewal date.

Updated on 13 June 2013 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Free text change information supplied by the pharmaceutical company

Additional method of usage registered

Updated on 13 June 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Additional method of usage registered

Updated on 12 April 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Update to description.

Updated on 12 April 2013 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Free text change information supplied by the pharmaceutical company

Update to description.

Updated on 11 January 2013 PIL

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Free text change information supplied by the pharmaceutical company

Replace stomach discomfort with stomach discomfort and/or pain.

Updated on 11 January 2013 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Replace stomach discomfort with stomach discomfort and/or pain.

Updated on 6 April 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Update to include reference to the printing ink and the patch dimensions.

Updated on 6 April 2011 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Free text change information supplied by the pharmaceutical company

Update to include reference to the printing ink and the patch dimensions.

Updated on 25 November 2008 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Supply through general sale

Updated on 25 November 2008 PIL

Reasons for updating

  • New SPC for new product